Thomas E Witzig (Thomas Witzig)

ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 101

Top Venues

American journal of hematology

Blood advances

Blood cancer journal

Leukemia & lymphoma

Mayo Clinic

Illinois State University (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Mayo Clinic Jul 01 1986

United States

MD :: Hematology

Education History

Illinois State University Sep 01 1971 - May 30 1975

United States

BSC :: Biology

Publications

Allison M Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew John Maurer, Amy Ayers, Brad S Kahl, Peter Martin, Jonathon B Cohen, Carla Casulo, Izidore S Lossos, Umar Farooq, Sabarish Ayyappan, Tanner Reicks, Thomas M Habermann, Thomas E Witzig, Christopher R Flowers, James R Cerhan, Loretta J Nastoupil, Grzegorz S Nowakowski
Defining primary refractory large B-cell lymphoma. Blood advances 8 (13) (2024)
Jessica F Burlile, Kelsey M Frechette, William G Breen, Steven R Hwang, Alexandra S Higgins, Adrienne N Nedved, William S Harmsen, Sydney D Pulsipher, Thomas E Witzig, Ivana N Micallef, Bradford S Hoppe, Thomas M Habermann, Gita Thanarajasingam, Patrick B Johnston, David J Inwards, N Nora Bennani, Jennifer L Peterson, Bradley J Stish, William G Rule, Stephen M Ansell, Scott C Lester
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy. Blood advances 8 (5) (2024)
Thomas E Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz Vicente, Alejandro Martin Martin Garcia-Sancho, Ranjana Advani, Jose Maria Roncero Vidal, Raquel de Oña Navarrete, Ana Marín-Niebla, Antonia Rodriguez Izquierdo, Maria José Terol, Eva Domingo-Domenech, Andrew Saunders, Nawal Bendris, Julie Mackey, Mollie Leoni, Francine M Foss
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood advances 8 (17) (2024)
Huong L Truong, Jason N Barreto, Kristin C Cole, Paul Joseph Hampel, Ivana N Micallef, Grzegorz S Nowakowski, Gita Thanarajasingam, Carrie A Thompson, Yucai Wang, Thomas E Witzig, Sandra M Herrmann, Nelson R Leung
Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO oncology practice 20 (6) (2024)
Allison M Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew John Maurer, Amy Ayers, Brad S Kahl, Peter Martin, Jonathon B Cohen, Carla Casulo, Izidore S Lossos, Umar Farooq, Sabarish Ayyappan, Tanner Reicks, Thomas M Habermann, Thomas E Witzig, Christopher R Flowers, James R Cerhan, Loretta J Nastoupil, Grzegorz S Nowakowski
Defining primary refractory large B-cell lymphoma. Blood advances 8 (13) (2024)
James R Cerhan, Matthew John Maurer, Brian L Link, Andrew L Feldman, Thomas M Habermann, David L Jaye, W Richard Burack, Timothy J McDonnell, Francisco Vega, Jennifer R Chapman, Sergei Syrbu, Kiran R Vij, Giorgio Inghirami, John P Leonard, Leon Bernal-Mizrachi, Umar Farooq, Thomas E Witzig, George J Weiner, Yucai Wang, Juan Pablo Alderuccio, Susan L Slager, Melissa C Larson, Shaun M Riska, Brianna J Gysbers, Julianne J Lunde, Tanner W Reicks, Amy A Ayers, Colin B O'Leary, Kathleen J Yost, Hongfang Liu, Grzegorz S Nowakowski, Jia Ruan, Dai Chihara, Jean L Koff, Carla Casulo, Carrie A Thompson, Jonathon B Cohen, Brad S Kahl, Loretta J Nastoupil, Izidore S Lossos, Jonathan W Friedberg, Peter Martin, Christopher R Flowers
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. American journal of hematology 99 (3) (2024)
James R Cerhan, Matthew John Maurer, Brian L Link, Andrew L Feldman, Thomas M Habermann, David L Jaye, W Richard Burack, Timothy J McDonnell, Francisco Vega, Jennifer R Chapman, Sergei Syrbu, Kiran R Vij, Giorgio Inghirami, John P Leonard, Leon Bernal-Mizrachi, Umar Farooq, Thomas E Witzig, George J Weiner, Yucai Wang, Juan Pablo Alderuccio, Susan L Slager, Melissa C Larson, Shaun M Riska, Brianna J Gysbers, Julianne J Lunde, Tanner W Reicks, Amy A Ayers, Colin B O'Leary, Kathleen J Yost, Hongfang Liu, Grzegorz S Nowakowski, Jia Ruan, Dai Chihara, Jean L Koff, Carla Casulo, Carrie A Thompson, Jonathon B Cohen, Brad S Kahl, Loretta J Nastoupil, Izidore S Lossos, Jonathan W Friedberg, Peter Martin, Christopher R Flowers
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. American journal of hematology 99 (3) (2024)
Huong L Truong, Jason N Barreto, Kristin C Cole, Paul Joseph Hampel, Ivana N Micallef, Grzegorz S Nowakowski, Gita Thanarajasingam, Carrie A Thompson, Yucai Wang, Thomas E Witzig, Sandra M Herrmann, Nelson R Leung
Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO oncology practice (2024)
James R Cerhan, Matthew John Maurer, Brian L Link, Andrew L Feldman, Thomas M Habermann, David L Jaye, W Richard Burack, Timothy J McDonnell, Francisco Vega, Jennifer R Chapman, Sergei Syrbu, Kiran R Vij, Giorgio Inghirami, John P Leonard, Leon Bernal-Mizrachi, Umar Farooq, Thomas E Witzig, George J Weiner, Yucai Wang, Juan Pablo Alderuccio, Susan L Slager, Melissa C Larson, Shaun M Riska, Brianna J Gysbers, Julianne J Lunde, Tanner W Reicks, Amy A Ayers, Colin B O'Leary, Kathleen J Yost, Hongfang Liu, Grzegorz S Nowakowski, Jia Ruan, Dai Chihara, Jean L Koff, Carla Casulo, Carrie A Thompson, Jonathon B Cohen, Brad S Kahl, Loretta J Nastoupil, Izidore S Lossos, Jonathan W Friedberg, Peter Martin, Christopher R Flowers
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. American journal of hematology (2024)
Arushi Khurana, Raphael Mwangi, Loretta J Nastoupil, Patrick M Reagan, Umar Farooq, Jason T Romancik, Timothy McDonnell, Shaun Riska, Izidore S Lossos, Brad S Kahl, Peter Martin, Thomas E Witzig, James R Cerhan, Christopher R Flowers, Grzegorz S Nowakowski, Matthew John Maurer
Evaluating Lab-Based Eligibility Criteria by Race/Ethnicity in Clinical Trials of Diffuse Large B-Cell Lymphoma. Blood advances (2024)
Kerstin Wenzl, Matthew E Stokes, Joseph P Novak, Allison M Bock, Sana Khan, Melissa A Hopper, Jordan Edward Krull, Abigail R Dropik, Janek S Walker, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C Chris Huang, Matthew John Maurer, Lisa Rimsza, Brian K Link, Susan L Slager, Yan Asmann, Patrizia Mondello, Ryan Morin, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Andrew L Feldman, Rebecca L King, Grzegorz S Nowakowski, James R Cerhan, Anita K Gandhi, Anne J Novak
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood cancer journal 14 (1) (2024)
Arushi Khurana, Raphael Mwangi, Loretta J Nastoupil, Patrick M Reagan, Umar Farooq, Jason T Romancik, Timothy J McDonnell, Shaun M Riska, Izidore S Lossos, Brad S Kahl, Peter Martin, Thomas E Witzig, James R Cerhan, Christopher R Flowers, Grzegorz S Nowakowski, Matthew John Maurer
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL. Blood advances 8 (16) (2024)
Chonlada Laoruangroj, Thomas M Habermann, Yucai Wang, Rebecca L King, Scott C Lester, Carrie A Thompson, Thomas E Witzig
Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori ? JCO oncology practice (2024)
Allison M Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew John Maurer, Amy Ayers, Brad S Kahl, Peter Martin, Jonathon B Cohen, Carla Casulo, Izidore S Lossos, Umar Farooq, Sabarish Ayyappan, Tanner Wayne Reicks, Thomas M Habermann, Thomas E Witzig, Christopher R Flowers, James R Cerhan, Loretta J Nastoupil, Grzegorz S Nowakowski
Defining Primary Refractory Large B-cell Lymphoma. Blood advances (2024)
Karan L Chohan, Rajiv K Pruthi, Saurabh Zanwar, Jonas Paludo, Ronald S Go, Animesh Pardanani, Aneel Ashrani, Joselle Madonna Cook, Carrie A Thompson, Asher Chanan-Khan, Sikandar Ailawadhi, Thomas M Habermann, Thomas E Witzig, Morie A Gertz, David Dingli, Francis K Buadi, Angela Dispenzieri, Nelson R Leung, Shaji K Kumar, Sundararajan Vincent Rajkumar, William L Nichols, Robert A Kyle, Stephen M Ansell, Prashant Kapoor, Meera Sridharan, Jithma A Abeykoon
The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events. Leukemia (2024)
Nadine H Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, Peter Leif Bergsagel, Sundararajan Vincent Rajkumar
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up. Leukemia 38 (5) (2024)
Chonlada Laoruangroj, Pamela J Atherton, Gregory A Wiseman, Stephen Ansell, Andrew L Feldman, Peyton Schumacher, Thomas E Witzig
The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma. Leukemia & lymphoma 65 (3) (2024)
Chonlada Laoruangroj, Thomas M Habermann, Yucai Wang, Rebecca L King, Scott C Lester, Carrie A Thompson, Thomas E Witzig
Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori ? JCO oncology practice 20 (8) (2024)
Chonlada Laoruangroj, Pamela J Atherton, Gregory A Wiseman, Stephen Ansell, Andrew L Feldman, Peyton Schumacher, Thomas E Witzig
The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma. Leukemia & lymphoma (2024)
Kerstin Wenzl, Matthew E Stokes, Joseph P Novak, Allison M Bock, Sana Khan, Melissa A Hopper, Jordan Edward Krull, Abigail R Dropik, Janek S Walker, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C Chris Huang, Matthew John Maurer, Lisa Rimsza, Brian K Link, Susan L Slager, Yan Asmann, Patrizia Mondello, Ryan Morin, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Andrew L Feldman, Rebecca L King, Grzegorz S Nowakowski, James R Cerhan, Anita K Gandhi, Anne J Novak
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood cancer journal 14 (1) (2024)
Nadine H Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, Peter Leif Bergsagel, Sundararajan Vincent Rajkumar
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up. Leukemia 38 (5) (2024)
Jessica F Burlile, Kelsey M Frechette, William G Breen, Steven R Hwang, Alexandra Higgins, Adrienne N Nedved, William S Harmsen, Sydney D Pulsipher, Thomas E Witzig, Ivana N Micallef, Bradford S Hoppe, Thomas M Habermann, Gita Thanarajasingam, Patrick B Johnston, David J Inwards, N Nora Bennani, Jennifer L Peterson, Bradley Stish, William G Rule, Stephen M Ansell, Scott C Lester
Patterns of Progression After Immune Checkpoint Inhibitors for Hodgkin Lymphoma: Implications for Radiation Therapy. Blood advances (2024)
Chonlada Laoruangroj, Thomas M Habermann, Yucai Wang, Rebecca L King, Scott C Lester, Carrie A Thompson, Thomas E Witzig
Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori ? JCO oncology practice 20 (8) (2024)
Mitchell Reed Smith, Opeyemi A Jagede, Peter Martin, Brian Till, Samir Parekh, David T Yang, Eric D Hsi, Thomas E Witzig, Sandeep S Dave, David W Scott, Curtis A Hanson, Lale Kostakoglu, Nizar N Abdel Samad, Carla Casulo, Nancy L Bartlett, Paolo F Caimi, Tareq Al Baghdadi, Kristie Blum, Mark Romer, David J Inwards, Rachel Lerner, Lynne I Wagner, Richard F Little, Jonathan W Friedberg, John P Leonard, Brad S Kahl
Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma. Blood (2024)
James R Cerhan, Matthew John Maurer, Brian L Link, Andrew L Feldman, Thomas M Habermann, David L Jaye, W Richard Burack, Timothy J McDonnell, Francisco Vega, Jennifer R Chapman, Sergei Syrbu, Kiran R Vij, Giorgio Inghirami, John P Leonard, Leon Bernal-Mizrachi, Umar Farooq, Thomas E Witzig, George J Weiner, Yucai Wang, Juan Pablo Alderuccio, Susan L Slager, Melissa C Larson, Shaun M Riska, Brianna J Gysbers, Julianne J Lunde, Tanner W Reicks, Amy A Ayers, Colin B O'Leary, Kathleen J Yost, Hongfang Liu, Grzegorz S Nowakowski, Jia Ruan, Dai Chihara, Jean L Koff, Carla Casulo, Carrie A Thompson, Jonathon B Cohen, Brad S Kahl, Loretta J Nastoupil, Izidore S Lossos, Jonathan W Friedberg, Peter Martin, Christopher R Flowers
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. American journal of hematology 99 (3) (2024)
Jessica F Burlile, Kelsey M Frechette, William G Breen, Steven R Hwang, Alexandra S Higgins, Adrienne N Nedved, William S Harmsen, Sydney D Pulsipher, Thomas E Witzig, Ivana N Micallef, Bradford S Hoppe, Thomas M Habermann, Gita Thanarajasingam, Patrick B Johnston, David J Inwards, N Nora Bennani, Jennifer L Peterson, Bradley J Stish, William G Rule, Stephen M Ansell, Scott C Lester
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy. Blood advances 8 (5) (2024)
James R Cerhan, Matthew John Maurer, Brian L Link, Andrew L Feldman, Thomas M Habermann, David L Jaye, W Richard Burack, Timothy J McDonnell, Francisco Vega, Jennifer R Chapman, Sergei Syrbu, Kiran R Vij, Giorgio Inghirami, John P Leonard, Leon Bernal-Mizrachi, Umar Farooq, Thomas E Witzig, George J Weiner, Yucai Wang, Juan Pablo Alderuccio, Susan L Slager, Melissa C Larson, Shaun M Riska, Brianna J Gysbers, Julianne J Lunde, Tanner W Reicks, Amy A Ayers, Colin B O'Leary, Kathleen J Yost, Hongfang Liu, Grzegorz S Nowakowski, Jia Ruan, Dai Chihara, Jean L Koff, Carla Casulo, Carrie A Thompson, Jonathon B Cohen, Brad S Kahl, Loretta J Nastoupil, Izidore S Lossos, Jonathan W Friedberg, Peter Martin, Christopher R Flowers
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. American journal of hematology 99 (3) (2024)
Chonlada Laoruangroj, Pamela J Atherton, Gregory A Wiseman, Stephen Ansell, Andrew L Feldman, Peyton Schumacher, Thomas E Witzig
The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma. Leukemia & lymphoma 65 (3) (2024)
Thomas E Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz, Alejandro Martin Martin Garcia-Sancho, Ranjana H Advani, Josep Maria Roncero Vidal, Raquel De Oña, Ana Marin-Niebla, Antonia Rodriguez Izquierdo, Maria José Terol, Eva Domingo-Domenech, Andrew Saunders, Nawal Bendris, Julie Mackey, Mollie Leoni, Francine M Foss
Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib for Relapsed/Refractory Peripheral T Cell Lymphoma. Blood advances (2024)
Kerstin Wenzl, Matthew E Stokes, Joseph P Novak, Allison M Bock, Sana Khan, Melissa A Hopper, Jordan Edward Krull, Abigail R Dropik, Janek S Walker, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C Chris Huang, Matthew John Maurer, Lisa Rimsza, Brian K Link, Susan L Slager, Yan Asmann, Patrizia Mondello, Ryan Morin, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Andrew L Feldman, Rebecca L King, Grzegorz S Nowakowski, James R Cerhan, Anita K Gandhi, Anne J Novak
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood cancer journal 14 (1) (2024)
Nadine H Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, Peter Leif Bergsagel, Sundararajan Vincent Rajkumar
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up. Leukemia (2024)
Thomas E Witzig, Lubomir Sokol, Won Seog Kim, Fátima de la Cruz Vicente, Alejandro Martin Martin Garcia-Sancho, Ranjana Advani, Jose Maria Roncero Vidal, Raquel de Oña Navarrete, Ana Marín-Niebla, Antonia Rodriguez Izquierdo, Maria José Terol, Eva Domingo-Domenech, Andrew Saunders, Nawal Bendris, Julie Mackey, Mollie Leoni, Francine M Foss
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood advances 8 (17) (2024)
James R Cerhan, Matthew John Maurer, Brian L Link, Andrew L Feldman, Thomas M Habermann, David L Jaye, W Richard Burack, Timothy J McDonnell, Francisco Vega, Jennifer R Chapman, Sergei Syrbu, Kiran R Vij, Giorgio Inghirami, John P Leonard, Leon Bernal-Mizrachi, Umar Farooq, Thomas E Witzig, George J Weiner, Yucai Wang, Juan Pablo Alderuccio, Susan L Slager, Melissa C Larson, Shaun M Riska, Brianna J Gysbers, Julianne J Lunde, Tanner W Reicks, Amy A Ayers, Colin B O'Leary, Kathleen J Yost, Hongfang Liu, Grzegorz S Nowakowski, Jia Ruan, Dai Chihara, Jean L Koff, Carla Casulo, Carrie A Thompson, Jonathon B Cohen, Brad S Kahl, Loretta J Nastoupil, Izidore S Lossos, Jonathan W Friedberg, Peter Martin, Christopher R Flowers
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. American journal of hematology 99 (3) (2024)
Allison M Bock, Raphael Mwangi, Yucai Wang, Arushi Khurana, Matthew John Maurer, Amy Ayers, Brad S Kahl, Peter Martin, Jonathon B Cohen, Carla Casulo, Izidore S Lossos, Umar Farooq, Sabarish Ayyappan, Tanner Reicks, Thomas M Habermann, Thomas E Witzig, Christopher R Flowers, James R Cerhan, Loretta J Nastoupil, Grzegorz S Nowakowski
Defining primary refractory large B-cell lymphoma. Blood advances 8 (13) (2024)
Kerstin Wenzl, Matthew E Stokes, Joseph P Novak, Allison M Bock, Sana Khan, Melissa A Hopper, Jordan Edward Krull, Abigail R Dropik, Janek S Walker, Vivekananda Sarangi, Raphael Mwangi, Maria Ortiz, Nicholas Stong, C Chris Huang, Matthew John Maurer, Lisa Rimsza, Brian K Link, Susan L Slager, Yan Asmann, Patrizia Mondello, Ryan Morin, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Andrew L Feldman, Rebecca L King, Grzegorz S Nowakowski, James R Cerhan, Anita K Gandhi, Anne J Novak
Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood cancer journal 14 (1) (2024)
Kang Le, Jordan Vollenweider, JingJing Han, Nicholas Staudinger, Mary Stenson, Lara Bayraktar, Linda E Wellik, Matthew J Maurer, Ellen Darcy McPhail, Thomas E Witzig, Mamta Gupta
Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach. Hematological oncology (2023)
Karan L Chohan, Jonas Paludo, Nishanth Vallumsetla, Dirk Larson, Rebecca L King, Rong He, Wilson I Gonsalves, David J Inwards, Thomas E Witzig, Abhisek Swaika, Tania Jain, Nelson R Leung, Sikandar Ailawadhi, Craig B Reeder, Martha Q Lacy, Sundararajan Vincent Rajkumar, Shaji K Kumar, Robert A Kyle, Morie A Gertz, Stephen M Ansell, Prashant Kapoor
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience. American journal of hematology 98 (3) (2023)
Cristina Correia, Matthew John Maurer, Samantha J McDonough, Paula A Schneider, Paige E Ross, Anne J Novak, Andrew L Feldman, James R Cerhan, Susan L Slager, Thomas E Witzig, Bruce W Eckloff, Hu Li, Grzegorz S Nowakowski, Scott H Kaufmann
Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era. Blood cancer journal 13 (1) (2023)
Saurabh Zanwar, Jithma P Abeykoon, Stephen M Ansell, Morie A Gertz, Michelle Mauermann, Thomas E Witzig, Patrick Johnston, Robert A Kyle, Rebecca L King, Thomas M Habermann, Shaji K Kumar, Prashant Kapoor
Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenström macroglobulinemia. Leukemia & lymphoma (2023)
Karan L Chohan, Jonas Paludo, Nishanth Vallumsetla, Dirk Larson, Rebecca L King, Rong He, Wilson I Gonsalves, David J Inwards, Thomas E Witzig, Abhisek Swaika, Tania Jain, Nelson R Leung, Sikandar Ailawadhi, Craig B Reeder, Martha Q Lacy, Sundararajan Vincent Rajkumar, Shaji K Kumar, Robert A Kyle, Morie A Gertz, Stephen M Ansell, Prashant Kapoor
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience. American journal of hematology 98 (3) (2023)
Allison M Bock, Jennifer Jane Gile, Melissa C Larson, Kittika Poonsombudlert, Reema K Tawfiq, Seth Maliske, Matthew John Maurer, Brian F Kabat, Jonas Paludo, David J Inwards, Sabarish Ayyappan, Brian K Link, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Grzegorz S Nowakowski, James R Cerhan, Umar Farooq, Yucai Wang
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood cancer journal 13 (1) (2023)
Matteo Passerini, Tamar Ratishvili, Jonathon M Monroe, Zelalem Temesgen, Thomas E Witzig, Neil E Kay, Richard B Kennedy, Sameer A Parikh
Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia. Leukemia & lymphoma (2023)
Cristina Correia, Matthew John Maurer, Samantha J McDonough, Paula A Schneider, Paige E Ross, Anne J Novak, Andrew L Feldman, James R Cerhan, Susan L Slager, Thomas E Witzig, Bruce W Eckloff, Hu Li, Grzegorz S Nowakowski, Scott H Kaufmann
Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era. Blood cancer journal 13 (1) (2023)
Karan L Chohan, Jonas Paludo, Nishanth Vallumsetla, Dirk Larson, Rebecca L King, Rong He, Wilson I Gonsalves, David J Inwards, Thomas E Witzig, Abhisek Swaika, Tania Jain, Nelson R Leung, Sikandar Ailawadhi, Craig B Reeder, Martha Q Lacy, Sundararajan Vincent Rajkumar, Shaji K Kumar, Robert A Kyle, Morie A Gertz, Stephen M Ansell, Prashant Kapoor
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience. American journal of hematology 98 (3) (2023)
Karan L Chohan, Jonas Paludo, Nishanth Vallumsetla, Dirk Larson, Rebecca L King, Rong He, Wilson I Gonsalves, David J Inwards, Thomas E Witzig, Abhisek Swaika, Tania Jain, Nelson R Leung, Sikandar Ailawadhi, Craig B Reeder, Martha Q Lacy, Sundararajan Vincent Rajkumar, Shaji K Kumar, Robert A Kyle, Morie A Gertz, Stephen M Ansell, Prashant Kapoor
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience. American journal of hematology (2023)
Karan L Chohan, Jonas Paludo, Nishanth Vallumsetla, Dirk Larson, Rebecca L King, Rong He, Wilson I Gonsalves, David J Inwards, Thomas E Witzig, Abhisek Swaika, Tania Jain, Nelson R Leung, Sikandar Ailawadhi, Craig B Reeder, Martha Q Lacy, Sundararajan Vincent Rajkumar, Shaji K Kumar, Robert A Kyle, Morie A Gertz, Stephen M Ansell, Prashant Kapoor
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience. American journal of hematology 98 (3) (2023)
Cristina Correia, Matthew John Maurer, Samantha J McDonough, Paula A Schneider, Paige E Ross, Anne J Novak, Andrew L Feldman, James R Cerhan, Susan L Slager, Thomas E Witzig, Bruce W Eckloff, Hu Li, Grzegorz S Nowakowski, Scott H Kaufmann
Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era. Blood cancer journal 13 (1) (2023)
Evandro D Bezerra, Madiha Iqbal, Javier Munoz, Arushi Khurana, Yucai Wang, Matthew John Maurer, Radhika Bansal, Matthew Hathcok, N Nora Bennani, Hemant S Murthy, Allison C Rosenthal, Jonas Paludo, Jose C Villasboas Bisneto, Patrick B Johnston, Thomas M Habermann, Stephen M Ansell, Januario E Castro, Thomas E Witzig, Mohamed A Kharfan-Dabaja, Grzegorz S Nowakowski, Yi Lin
Barriers to enrollment in clinical trials of patients with aggressive B-Cell NHL that progressed after CAR T-cell therapy. Blood advances (2022)
Aung M Tun, Arushi Khurana, Raphael Mwangi, Brian L Link, Yucai Wang, Andrew L Feldman, Carrie A Thompson, Anne J Novak, Jose C Villasboas Bisneto, Gita Thanarajasingam, Umar Farooq, Sergei Syrbu, Grzegorz S Nowakowski, Thomas E Witzig, Stephen M Ansell, Lisa M Rimsza, James R Cerhan, Thomas M Habermann, Matthew John Maurer
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood advances 6 (17) (2022)
Nadine H Abdallah, Thomas M Habermann, Francis K Buadi, Morie A Gertz, Martha Q Lacy, Sundararajan Vincent Rajkumar, David Dingli, Ronald S Go, Suzanne R Hayman, Shaji K Kumar, Taxiarchis V Kourelis, Rahma M Warsame, Prashant Kapoor, Eli Muchtar, Yi Lisa Hwa, Amie L Fonder, Miriam A Hobbs, Yi Lin, Nelson R Leung, Moritz Binder, Mustaqeem A Siddiqui, Robert A Kyle, Thomas E Witzig, Angela Dispenzieri
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. American journal of hematology 97 (4) (2022)
Sanjal H Desai, Raphael Mwangi, Alexandra N Smith, Matthew J Maurer, Umar Farooq, Rebecca L King, James R Cerhan, Andrew L Feldman, Thomas M Habermann, Carrie A Thompson, Yucai Wang, Stephen M Ansell, Thomas E Witzig, Grzegorz S Nowakowski
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma. Hematological oncology (2022)
Karan Seegobin, Zhuo Li, Muhamad Alhaj Moustafa, Umair Majeed, Jing Wang, Liuyan Jiang, Justin J Kuhlman, David Menke, Ke Li, Mohamed A Kharfan-Dabaja, Ernesto Ayala, Madiha Iqbal, Grzegorz S Nowakowski, Thomas M Habermann, Thomas E Witzig, Patrick Johnston, Carrie Thompson, Stephen M Ansell, Han W Tun
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018). American journal of hematology 97 (9) (2022)
Karan L Chohan, Jithma A Abeykoon, Stephen M Ansell, Morie A Gertz, Prashant Kapoor, Aneel Paulus, Sikandar Ailawadhi, Craig B Reeder, Thomas E Witzig, Thomas M Habermann, Martha Q Lacy, Robert A Kyle, Ronald S Go, Jonas Paludo
Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States. Leukemia & lymphoma 63 (12) (2022)
Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie-Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas E Witzig
Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial. Cancer reports (Hoboken, N.J.) (2022)
Yucai Wang, Shouhao Zhou, Xinyue Qi, Fang Yang, Matthew John Maurer, Thomas M Habermann, Thomas E Witzig, Michael L Wang, Grzegorz S Nowakowski
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood cancer journal 12 (1) (2022)
Joselle Cook, Kah-Whye Peng, Thomas E Witzig, Stephen M Broski, Jose C Villasboas Bisneto, Jonas Paludo, Mirinal S Patnaik, Vincent Rajkumar, Angela Dispenzieri, Nelson R Leung, Francis K Buadi, N Nora Bennani, Stephen M Ansell, Lianwen Zhang, Nandakumar Packiriswamy, Baskar Balakrishnan, Bethany Brunton, Marissa Giers, Brenda Ginos, Amylou C Dueck, Susan Geyer, Morie A Gertz, Rahma M Warsame, Ronald S Go, Suzanne R Hayman, David Dingli, Shaji K Kumar, Peter Leif Bergsagel, Javier L Munoz, Wilson Gonsalves, Taxiarchis V Kourelis, Eli Muchtar, Prashant Kapoor, Robert A Kyle, Yi Lin, Mustaqeem A Siddiqui, Amie L Fonder, Miriam Hobbs, Lisa Hwa, Shruthi Naik, Stephen J Russell, Martha Q Lacy
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood advances 6 (11) (2022)
Jithma A Abeykoon, Terra L Lasho, Surendra Dasari, Karen L Rech, Wasantha K Ranatunga, Michelle K Manske, Alexander Tischer, Aishwarya Ravindran, Jason R Young, William Oliver Tobin, Eoin P Flanagan, Kevin E Nowakowski, Gordon J Ruan, Mithun Vinod Shah, Nabila Nora Bennani, Robert Vassallo, Jay H Ryu, Matthew J Koster, Caroline J Davidge-Pitts, Mirinal S Patnaik, Xiaosheng Wu, Thomas E Witzig, Gaurav Goyal, Ronald S Go, null null
Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease. American journal of hematology 97 (3) (2022)
Sanjal H Desai, Raphael Mwangi, Wern Lynn Ng, Rebecca L King, Matthew John Maurer, James R Cerhan, Andrew L Feldman, Umar Farooq, Eric Mou, Thomas M Habermann, Carrie A Thompson, Yucai Wang, Thomas E Witzig, Grzegorz S Nowakowski
Increasing tissue requirements in lymphoma trials may exclude patients with high risk disease or worse prognosis. Blood advances (2022)
Darragh F O'Donoghue, Huong L Truong, Heidi D Finnes, Jennifer S McDonald, Heather Personett May, Stephen M Ansell, N Nora Bennani, Thomas M Habermann, David J Inwards, Patrick B Johnston, Arushi Khurana, Yi Lin, Ivana N Micallef, Grzegorz S Nowakowski, Jonas Paludo, Luis F Porrata, Gita Thanarajasingam, Carrie A Thompson, Jose C Villasboas Bisneto, Yucai Wang, Thomas E Witzig, Nelson R Leung
High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course. JCO oncology practice (2022)
Kristine Broglio, Lale Kostakoglu, Carol Ward, Federico Mattiello, Denis Sahin, Tina Nielsen, Anna McGlothlin, Corrine F Elliott, Thomas E Witzig, Laurie Helen Sehn, Marek Trněný, Umberto Vitolo, Maurizio Martelli, Margaret J Foster, Barbara A Wendelberger, Grzegorz Nowakowski, Donald A Berry
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. Leukemia & lymphoma 63 (12) (2022)
Nicole R McLaughlin, Yucai Wang, Thomas E Witzig, Jose Villasboas, Thomas Habermann, David Inwards, N Nora Bennani, Gita Thanarajasingam, Grzegorz Nowakowski, Luis Porrata, Carrie Thompson, Ivana Micallef, Patrick Johnston, Stephen Ansell, Jonas Paludo
Central nervous system involvement by mantle cell lymphoma. Leukemia & lymphoma (2022)
Surbhi Sidana, Cristine Allmer, Melissa C Larson, Amylou C Dueck, Kathleen J Yost, Rahma M Warsame, Gita Thanarajasingam, James R Cerhan, Jonas Paludo, S Vincent Rajkumar, Thomas M Habermann, Grzegorz S Nowakowski, Yi Lin, Morie A Gertz, Thomas E Witzig, Angela Dispenzieri, Wilson I Gonsalves, Stephen M Ansell, Carrie A Thompson, Shaji K Kumar
Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO oncology practice 18 (8) (2022)
Jason N Barreto, Joel M Reid, Carrie A Thompson, Kristin C Cole, Andrew D Rule, Kianoush B Kashani, Nelson R Leung, Thomas R Larson, Renee M McGovern, Thomas E Witzig, Erin F Barreto
Propsective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function. Clinical and translational science (2021)
Alexandra S Higgins, Hidong Kim, Laura Harper, Thomas M Habermann, Grzegorz S Nowakowski, Carrie A Thompson, Patrick Johnston, Thomas E Witzig, Cristine Allmer, Matthew John Maurer, James R Cerhan, Jason R Young, Gita Thanarajasingam
Testicular FDG-PET/CT uptake threshold in aggressive lymphomas. American journal of hematology 96 (3) (2021)
Patrizia Mondello, Angelo Fama, Melissa C Larson, Andrew L Feldman, Jose C Villasboas Bisneto, Zhi-Zhang Yang, Ilia Galkin, Viktor Svelolkin, Ekaterina Postovalova, Alexander Bagaev, Pavel Ovcharov, Arina Varlamova, Sarah Huet, Bruno Tesson, Kaitlyn R McGrath, Susan L Slager, Brian K Link, Sergei Syrbu, Anne J Novak, Thomas M Habermann, Thomas E Witzig, Grzegorz S Nowakowski, Gilles Andre Salles, James R Cerhan, Stephen M Ansell
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood cancer journal 11 (7) (2021)
Zhuoer Xie, Antoine N Saliba, Jithma Abeykoon, Umair Majeed, Daniel R Almquist, Julia E Wiedmeier, Evandro Bezerra, Xavier Andrade-Gonzalez, Ashley Hickman, Karl Sorenson, Sagar Rakshit, Christopher E Wee, Sri Harsha Tella, Anuhya Kommalapati, Nadine Abdallah, Joshua C Pritchett, Mariza De Andrade, Dipesh Uprety, Andrew Badley, Rami Manochakian, Sikandar Ailawadhi, Alan H Bryce, Joleen M Hubbard, Naseema Gangat, Carrie A Thompson, Thomas E Witzig, Robert R McWilliams, Konstantinos Leventakos, Thorvardur R Halfdanarson
Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO oncology practice 17 (9) (2021)
Sanjal H Desai, Betsy LaPlant, William R Macon, Rebecca L King, Yucai Wang, David J Inwards, Ivana Micallef, Patrick B Johnston, Luis F Porrata, Stephen M Ansell, Thomas M Habermann, Thomas E Witzig, Grzegorz S Nowakowski
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood cancer journal 11 (9) (2021)
Kang Le, Linda E Wellik, Matthew John Maurer, Ellen Darcy McPhail, Thomas E Witzig, Mamta Gupta
JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. Blood cancer journal 11 (3) (2021)
Ryan M Carr, Denis Vorobyev, Terra Lasho, David L Marks, Ezequiel J Tolosa, Alexis Vedder, Luciana L Almada, Andrey Yurcheko, Ismael Padioleau, Bonnie Alver, Giacomo Coltro, Moritz Binder, Stephanie L Safgren, Isaac Horn, Xiaona You, Eric Solary, Maria E Balasis, Kurt Berger, James Hiebert, Thomas E Witzig, Ajinkya Buradkar, Temeida Graf, Peter Valent, Abhishek A Mangaonkar, Keith D Robertson, Matthew T Howard, Scott H Kaufmann, Christopher L Pin, Martin E Fernandez-Zapico, Klaus Geissler, Nathalie M Droin, Eric Padron, Jing Zhang, Sergey I Nikolaev, Mirinal S Patnaik
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nature communications 12 (1) (2021)
null Arushi Khurana, Raphael Mwangi, Stephen M Ansell, Thomas M Habermann, James R Cerhan, Christopher Strouse, Brian K Link, Yucai Wang, Rebecca L King, William R Macon, Jose C Villasboas Bisneto, Thomas E Witzig, Matthew John Maurer, Grzegorz S Nowakowski
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood cancer journal 11 (7) (2021)
Nicholas J Boddicker, Melissa C Larson, Alessia Castellino, Joerg Herrmann, David J Inwards, Gita Thanarajasingam, Matthew John Maurer, Cristine Allmer, Thomas E Witzig, Grzegorz S Nowakowski, Thomas M Habermann, Hector R Villarraga, Susan L Slager, James R Cerhan, Carrie A Thompson
Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American journal of hematology 96 (8) (2021)
Grzegorz S Nowakowski, Annalisa Chiappella, Randy D Gascoyne, David W Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Özcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan-Miguel Bergua, Francesco A Piazza, Heidi Mócikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E Witzig, Umberto Vitolo
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (12) (2021)
Jennifer Jane Gile, Camden L Lopez, Gordon J Ruan, Matthew A Hathcock, Jithma P Abeykoon, Joy R Heimgartner, Nikola A Baumann, M Molly McMahon, Ivana N Micallef, Patrick B Johnston, Jose C Villasboas Bisneto, Luis F Porrata, Jonas Paludo, Stephen M Ansell, William Joseph Hogan, Thomas E Witzig
Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. Blood cancer journal 11 (3) (2021)
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, William R Macon, Rebecca L King, Thomas M Habermann, Nina Wagner-Johnston, Carla Casulo, James L Wade, Gauri G Nagargoje, C M Reynolds, Jonathon B Cohen, Nadia Khan, Jennifer Effie Amengual, Kristy L Richards, Richard F Little, John P Leonard, Jonathan W Friedberg, Lale Kostakoglu, Brad S Kahl, Thomas E Witzig
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (12) (2021)
Jithma A Abeykoon, Saurabh Zanwar, Stephen M Ansell, Eli Muchtar, Rong He, Patricia T Greipp, Rebecca L King, Sikandar Ailawadhi, Jonas Paludo, Jeremy T Larsen, Thomas M Habermann, David J Inwards, Ronald S Go, Gita Thanarajasingam, Francis Buadi, Angela Dispenzieri, Carrie A Thompson, Thomas E Witzig, Martha Lacy, Wilson I Gonsalves, Grzegorz S Nowakowski, David Dingli, Sundararajan Vincent Rajkumar, Robert A Kyle, Taimur Sher, Vivek Roy, Allison C Rosenthal, Asher A Chanan-Khan, Craig Reeder, Morie A Gertz, Shaji K Kumar, Prashant Kapoor
Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. American journal of hematology 96 (8) (2021)
Robert M Kraft, Stephen M Ansell, Jose C Villasboas, N Nora Bennani, Yucai Wang, Thomas M Habermann, Gita Thanarajasingam, Scott C Lester, William Macon, David J Inwards, Luis F Porrata, Ivana N Micallef, Thomas E Witzig, Carrie A Thompson, Patrick B Johnston, Grzegorz S Nowakowski, Yi Lin, Jonas Paludo
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. Hematological oncology 39 (5) (2021)
Arushi Khurana, Raphael Mwangi, Grzegorz S Nowakowski, Thomas M Habermann, Stephen M Ansell, Betsy R LaPlant, Brian L Link, James R Cerhan, Matthew John Maurer, Thomas E Witzig
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (15) (2021)
Alessia Castellino, Yucai Wang, Melissa C Larson, Matthew John Maurer, Brian L Link, Umar Farooq, Andrew L Feldman, Sergei I Syrbu, Thomas M Habermann, Jonas Paludo, David J Inwards, Thomas E Witzig, Stephen M Ansell, Cristine Allmer, Susan L Slager, Jonathon B Cohen, Peter Martin, James R Cerhan, Grzegorz S Nowakowski
Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes. Blood advances (2021)
Ilyas Sahin, Yawara Kawano, Romanos Sklavenitis-Pistofidis, Michele Moschetta, Yuji Mishima, Salomon Manier, Antonio Sacco, Ruben Carrasco, Rafael Fonseca, Aldo M Roccaro, Thomas E Witzig, Irene M Ghobrial
Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood advances 3 (7) (2020)
Steven R Hwang, Alexandra S Higgins, Natalia E Castillo Almeida, Betsy LaPlant, Matthew John Maurer, Stephen M Ansell, Thomas E Witzig, Gita Thanarajasingam, N Nora Bennani
Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. Leukemia & lymphoma 62 (1) (2020)
Keenan T Hartert, Kerstin Wenzl, Jordan E Krull, Michelle Manske, Vivekananda Sarangi, Yan Asmann, Melissa C Larson, Matthew John Maurer, Susan Slager, William R Macon, Rebecca L King, Andrew L Feldman, Anita K Gandhi, Brian K Link, Thomas M Habermann, Zhi-Zhang Yang, Stephen M Ansell, James R Cerhan, Thomas E Witzig, Grzegorz S Nowakowski, Anne J Novak
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia 35 (2) (2020)
Andrew M Evens, Fangxin Hong, Thomas M Habermann, Ranjana H Advani, Randy D Gascoyne, Thomas E Witzig, Andrew Quon, Erik A Ranheim, Stephen M Ansell, Puneet Singh Cheema, Philip A Dy, Timothy E O'Brien, Jane N Winter, Terrence P Cescon, Julie E Chang, Brad S Kahl
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (17) (2020)
Madugodaralalage D S K Gunaratne, Alexander J Sahakian, Jithma A Abeykoon, Stephen M Ansell, Morie A Gertz, Prashant Kapoor, Aneel Paulus, Sikandar Ailawadhi, Craig B Reeder, Thomas E Witzig, Thomas M Habermann, Anne J Novak, Martha Q Lacy, Robert A Kyle, Ronald S Go, Jonas Paludo
Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leukemia & lymphoma 62 (2) (2020)
Saurabh Zanwar, Jithma A Abeykoon, Eric Durot, Rebecca King, Gabriela E Perez Burbano, Shaji Kumar, Morie A Gertz, Anne Quinquenel, Alain Delmer, Wilson I Gonsalves, Pascale Cornillet-Lefebvre, Rong He, Rahma M Warsame, Francis K Buadi, Anne J Novak, Patricia T Greipp, David Inwards, Thomas M Habermann, Ivana Micallef, Ronald Go, Eli Muchtar, Taxiarchis V Kourelis, Angela Dispenzieri, Martha Q Lacy, David Dingli, Grzegorz Nowakowski, Carrie A Thompson, Patrick Johnston, Gita Thanarajasingam, N Nora Bennani, Thomas E Witzig, Jose Villasboas, Nelson R Leung, Yi Lin, Robert A Kyle, Sundararajan Vincent Rajkumar, Stephen M Ansell, Jennifer G Le-Rademacher, Prashant Kapoor
Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. American journal of hematology 95 (3) (2019)
Thomas E Witzig, David Inwards
Acalabrutinib for mantle cell lymphoma. Blood 133 (24) (2019)
Yucai Wang, Thomas M Habermann, Sophia S Wang, Matthew J Maurer, Vivekananda Sarangi, Brian K Link, Andrew L Feldman, David J Inwards, Thomas E Witzig, Wendy Cozen, Nathaniel Rothman, Yan Asmann, Susan L Slager, James R Cerhan
Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study. American journal of hematology 94 (6) (2019)
Paul Joseph Hampel, Timothy G Call, Wei Ding, Eli Muchtar, Saad Sirop Kenderian, Yucai Wang, Jose F Leis, Thomas E Witzig, Amber B Koehler, Amie L Fonder, Susan M Schwager, Kari G Rabe, Daniel L Van Dyke, Esteban Braggio, Susan L Slager, Neil E Kay, Sameer A Parikh
Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. American journal of hematology 95 (3) (2019)
Jithma P Abeykoon, Jonas Paludo, Kevin E Nowakowski, Mary J Stenson, Rebecca L King, Linda E Wellik, Xiaosheng Wu, Thomas E Witzig
The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. Blood cancer journal 9 (3) (2019)
Xiaosheng Wu, Mary Stenson, Jithma Abeykoon, Kevin Nowakowski, Lianwen Zhang, Joshua Lawson, Linda Wellik, Ying Li, Jordan Krull, Kerstin Wenzl, Anne J Novak, Stephen M Ansell, Gail A Bishop, Daniel D Billadeau, Kah Whye Peng, Francis J Giles, Daniel M Schmitt, Thomas E Witzig
Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood 134 (4) (2019)
Grzegorz S Nowakowski, Tatyana Feldman, Lisa M Rimsza, Jason R Westin, Thomas E Witzig, Pier Luigi Zinzani
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood cancer journal 9 (6) (2019)
Frédérique St-Pierre, Stephen M Broski, Betsy R LaPlant, Kay Ristow, Matthew J Maurer, William R Macon, Thomas M Habermann, Stephen M Ansell, Carrie A Thompson, Ivana N M Micallef, Grzegorz S Nowakowski, Thomas E Witzig
Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. American journal of hematology 94 (7) (2019)
Alessia Castellino, Jose S Pulido, Patrick B Johnston, Kay M Ristow, N Nora Bennani, David J Inwards, William R Macon, Ivana N M Micallef, Rebecca L King, Diva R Salomao, Thomas E Witzig, Thomas M Habermann, Grzegorz S Nowakowski
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. American journal of hematology 94 (3) (2018)
Priyanka A Pophali, Andrew Ip, Melissa C Larson, Allison C Rosenthal, Matthew J Maurer, Christopher R Flowers, Brian K Link, Umar Farooq, Andrew L Feldman, Cristine Allmer, Susan L Slager, Thomas E Witzig, Thomas M Habermann, Jonathon B Cohen, James R Cerhan, Carrie A Thompson
The association of physical activity before and after lymphoma diagnosis with survival outcomes. American journal of hematology 93 (12) (2018)
Jithma A Abeykoon, Saurabh Zanwar, Stephen M Ansell, Jeffrey Winters, Morie A Gertz, Rebecca L King, David Murray, Thomas Habermann, David Dingli, Eli Muchtar, Ronald S Go, Nelson R Leung, David J Inwards, Francis K Buadi, Angela Dispenzieri, Martha Q Lacy, Yi Lin, Wilson I Gonsalves, Taxiarchis V Kourelis, Thomas E Witzig, Carrie Thompson, Sundararajan Vincent Rajkumar, Robert A Kyle, Shaji Kumar, Prashant Kapoor
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American journal of hematology 93 (11) (2018)
Thomas E Witzig, Pier Luigi Zinzani, Thomas M Habermann, Joseph M Tuscano, Johannes Drach, Radhakrishnan Ramchandren, Sevgi Kalayoglu Besisik, Kenichi Takeshita, Marie-Laure Casadebaig Bravo, Lei Zhang, Tommy Fu, Andre Goy
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. American journal of hematology 92 (10) (2017)
Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, Paul J Kurtin, Levi D Pederson, Dennis F Moore, Nassim H Nabbout, Daniel A Nikcevich, Kendrith M Rowland, Axel Grothey
Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). American journal of hematology 92 (10) (2017)
Allison C Rosenthal, Amylou C Dueck, Stephen Ansell, Katherine Gano, Christopher Conley, Grzegorz S Nowakowski, John Camoriano, Jose F Leis, Joseph R Mikhael, A Keith Stewart, David Inwards, David Dingli, Shaji Kumar, Pierre Noel, Morie Gertz, Luis Porrata, Stephen Russell, Joseph Colgan, Rafael Fonseca, Thomas M Habermann, Prashant Kapoor, Francis Buadi, Nelson Leung, Rodger Tiedemann, Thomas E Witzig, Craig Reeder
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. American journal of hematology 92 (5) (2017)
Jithma A Abeykoon, Jonas Paludo, Rebecca L King, Stephen M Ansell, Morie A Gertz, Betsy R LaPlant, Alese E Halvorson, Wilson I Gonsalves, David Dingli, Hong Fang, S Vincent Rajkumar, Martha Q Lacy, Rong He, Taxiarchis Kourelis, Craig B Reeder, Anne J Novak, Ellen D McPhail, David S Viswanatha, Thomas E Witzig, Ronald S Go, Thomas M Habermann, Francis K Buadi, Angela Dispenzieri, Nelson R Leung, Yi Lin, Carrie A Thompson, Suzanne R Hayman, Robert A Kyle, Shaji K Kumar, Prashant Kapoor
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. American journal of hematology 93 (2) (2017)
N Nora Bennani, Betsy R LaPlant, Stephen M Ansell, Thomas M Habermann, David J Inwards, Ivana N Micallef, Patrick B Johnston, Luis F Porrata, Joseph P Colgan, Svetomir N Markovic, Grzegorz S Nowakowski, William R Macon, Craig B Reeder, Joseph R Mikhael, Donald W Northfelt, Irene M Ghobrial, Thomas E Witzig
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. American journal of hematology 92 (5) (2017)
Moritz Binder, Megan M O'Byrne, Matthew J Maurer, Stephen Ansell, Andrew L Feldman, James Cerhan, Anne Novak, Luis F Porrata, Svetomir Markovic, Brian K Link, Thomas E Witzig
Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. American journal of hematology 92 (8) (2017)

Thomas E Witzig.css-eqlu8i{font-size:small;padding-left:4px;} (Thomas Witzig)

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas E Witzig (Thomas Witzig)